Actively Recruiting
Phase 12a Double-blind Study of ARO-DIMERPA Versus Placebo to Assess Safety and Effects on Cholesterol and Triglycerides in Adults with Mixed Hyperlipidemia
Led by Arrowhead Pharmaceuticals · Updated on 2026-10-13
78
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ARO-DIMERPA, a drug given by injection, in adults with mixed hyperlipidemia to study its safety, how the body processes it, and its effects on cholesterol and triglyceride levels. This study is a Phase 12a, double-blind, placebo-controlled trial designed to test single and multiple doses of ARO-DIMERPA compared to placebo in adult participants. Participants will receive either single or multiple escalating doses of ARO-DIMERPA or a matching placebo given by subcutaneous injection. The study uses a randomized, sequential design with quadruple masking to compare the effects of the drug and placebo. Treatment and monitoring will occur over a period extending up to 36 weeks. During the study, participants will be monitored for treatment-emergent side effects, and their cholesterol and triglyceride levels will be measured at baseline and throughout the 36 weeks. Researchers will also assess the drugs pharmacokinetics over 24 hours after dosing. Participants will have regular visits for evaluations, including blood tests to track safety and drug effects, with the study continuing until July 2027.
CONDITIONS
Brief Title
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Research Team
M
Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here